Evidence map›Paper›PMID 36189689›Full record

ReviewDiabetes care2022

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).

Ian H de Boer, Kamlesh Khunti, Tami Sadusky, Katherine R Tuttle, Joshua J Neumiller, Connie M Rhee, Sylvia E Rosas, Peter Rossing, George Bakris

Open access · greenAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 499 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
499citing papers in PubMed, 12 pooled it
98.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

499 citing papers in PubMed, 12 syntheses or guidelines pooled it, 762 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

439 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Ian H de BoerKidney Research Institute, University of Washington, Seattle, WA.ORCID 0000-0003-1571-7592
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester, U.K.
Tami SaduskyUniversity of Washington, Seattle, WA.
Katherine R TuttleUniversity of Washington, Spokane, WA.
Joshua J NeumillerCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA.
Connie M RheeUniversity of California, Irvine, Orange, CA.
Sylvia E RosasJoslin Diabetes Center and Harvard Medical School, Boston, MA.
Peter RossingSteno Diabetes Center Copenhagen, Copenhagen, Demark.
George BakrisUniversity of Chicago Medicine, Chicago, IL.
University of Washington · USWashington State University Spokane · USJoslin Diabetes Center · USUniversity of California, Irvine · USUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of Leicester · GB

Funding

PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
NIDDK NIH HHS P30 DK035816
6 · The paper itself

Abstract

People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.

Indexed as

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicHumansKidney

Identifiers

PMID36189689
PMCPMC9870667
OpenAlexW4300688387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.